Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, J.H.[Kwon, J.H.] | - |
dc.contributor.author | Bae, S.H.[ Bae, S.H.] | - |
dc.contributor.author | Choi, J.Y.[ Choi, J.Y.] | - |
dc.contributor.author | Yoon, S.K.[ Yoon, S.K.] | - |
dc.contributor.author | Byun, K.S.[ Byun, K.S.] | - |
dc.contributor.author | Paik, S.W.[Paik, S.W.] | - |
dc.contributor.author | Lim, Y.S.[ Lim, Y.S.] | - |
dc.contributor.author | Lee, H.C.[ Lee, H.C.] | - |
dc.contributor.author | Han, K.H.[ Han, K.H.] | - |
dc.contributor.author | Lee, K.S.[ Lee, K.S.] | - |
dc.date.accessioned | 2021-08-07T06:47:57Z | - |
dc.date.available | 2021-08-07T06:47:57Z | - |
dc.date.created | 2017-01-12 | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/79189 | - |
dc.description.abstract | Background/Aims: The virologic response of Koreans to combination therapy for chronic hepatitis C is similar to westerns; however, dose modification occurs more frequently in Koreans. We evaluated the rates of peginterferon α-2a and ribavirin dose modifications and their effect on the virologic response in Koreans. Methods: Patients with detectable HCV RNA and enrolled from multicenters were treated with peginterferon α-2a (180 μg/week) and ribavirin (800 mg/day) for 24 weeks (genotype non-1, n=37) or peginterferon α-2a (180 μg/ week) and ribavirin (1,000-1,200 mg/day) for 48 weeks (genotype 1, n=55). Results: Early virologic response (EVR) and sustained virologic response (SVR) were 77.2% (genotype 1, 75%; non-1, 81%) and 66.3% (genotype 1, 56%; non-1, 81%), respectively. The frequency of dose modification was 32.6% within the first 12 weeks and 52.2% during the entire treatment period. No difference was found in SVR regardless of dose modification. However, the SVR for patients using ≥80% of the peginterferon dose was significantly higher than for those using <80% (81.3 vs. 50.0%, p=0.007), despite varying ribavirin doses. No difference was found in SVR regardless of whether the ribavirin dose was <80% or not. These results did not change based on genotype. Conclusions: We suggest that using at least 80% of the peginterferon α-2a dose in Koreans not only maintains SVR but also reduces drug side effects during the entire treatment period. A lower dose of ribavirin may be as efficacious as a standard dose. | - |
dc.subject | peginterferon alpha2a | - |
dc.subject | ribavirin | - |
dc.subject | virus RNA | - |
dc.subject | alpha2a interferon | - |
dc.subject | antivirus agent | - |
dc.subject | macrogol derivative | - |
dc.subject | peginterferon alfa-2a | - |
dc.subject | peginterferon alpha2a | - |
dc.subject | ribavirin | - |
dc.subject | abdominal pain | - |
dc.subject | adult | - |
dc.subject | alanine aminotransferase blood level | - |
dc.subject | anemia | - |
dc.subject | article | - |
dc.subject | body weight | - |
dc.subject | chronic hepatitis | - |
dc.subject | drug dose reduction | - |
dc.subject | drug efficacy | - |
dc.subject | female | - |
dc.subject | genotype | - |
dc.subject | hepatitis C | - |
dc.subject | human | - |
dc.subject | Korea | - |
dc.subject | liver cirrhosis | - |
dc.subject | major clinical study | - |
dc.subject | male | - |
dc.subject | myalgia | - |
dc.subject | nausea | - |
dc.subject | neutropenia | - |
dc.subject | pruritus | - |
dc.subject | side effect | - |
dc.subject | thrombocytopenia | - |
dc.subject | treatment duration | - |
dc.subject | treatment outcome | - |
dc.subject | aged | - |
dc.subject | blood | - |
dc.subject | clinical trial | - |
dc.subject | drug combination | - |
dc.subject | middle aged | - |
dc.subject | multicenter study | - |
dc.subject | virology | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Antiviral Agents | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Female | - |
dc.subject | Hepatitis C, Chronic | - |
dc.subject | Humans | - |
dc.subject | Interferon Alfa-2a | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Polyethylene Glycols | - |
dc.subject | Ribavirin | - |
dc.subject | RNA, Viral | - |
dc.title | Assessment of the efficacy of reducing peginterferon alfa-2a and ribavirin dose on virologic response in Koreans with chronic hepatitis C | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Paik, S.W.[Paik, S.W.] | - |
dc.identifier.doi | 10.3904/kjim.2009.24.3.203 | - |
dc.identifier.scopusid | 2-s2.0-70449711352 | - |
dc.identifier.bibliographicCitation | Korean Journal of Internal Medicine, v.24, no.3, pp.203 - 211 | - |
dc.relation.isPartOf | Korean Journal of Internal Medicine | - |
dc.citation.title | Korean Journal of Internal Medicine | - |
dc.citation.volume | 24 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 203 | - |
dc.citation.endPage | 211 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | Koreans | - |
dc.subject.keywordAuthor | Peginterferon alfa-2a | - |
dc.subject.keywordAuthor | Ribavirin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.